The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 15, 2022
Filed:
Dec. 06, 2018
Applicant:
Oncobix Co., Ltd., Yongin-si, KR;
Inventors:
Sung-Eun Kim, Seoul, KR;
Sunho Lee, Seoul, KR;
Rengasamy Rajesh, Suwon-si, KR;
Dae Ho Kang, Goyang-si, KR;
Hyung Chui Ryu, Hwaseong-si, KR;
Jae-Sun Kim, Suwon-si, KR;
Sangryul Lee, Chungju-si, KR;
Kyong Cheol Kim, Chungju-si, KR;
Jin Kyung Rho, Seoul, KR;
Jae Cheol Lee, Seoul, KR;
Assignee:
ONCOBIX CO., LTD., Yongin-si, KR;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 401/14 (2006.01); C07D 403/14 (2006.01); A61K 31/506 (2006.01); A61P 35/00 (2006.01); C07D 495/04 (2006.01); C07D 401/12 (2006.01); C07D 473/16 (2006.01); C07D 487/04 (2006.01);
U.S. Cl.
CPC ...
C07D 495/04 (2013.01); A61P 35/00 (2018.01); C07D 401/12 (2013.01); C07D 473/16 (2013.01); C07D 487/04 (2013.01);
Abstract
A novel pyrimidine derivative compound and a salt thereof are disclosed. The pyrimidine derivative compound effectively inhibits the growth of C797S mutant EGFR-expressed and MET-amplified cancer cells, which are the main resistance mechanisms of third generation EGFR anticancer agents, and thus may be effectively used in the treatment of lung cancer.